Reporting owner · CIK 0001678984
Schilke Tobin
SEC Form 4 history across 1 companies, 5 transactions and 2 filings.
CF, IOChief Financial & Infra. Ofcr.Crinetics Pharmaceuticals, Inc.
Open-market transaction mix—0 buys · 0 sales
Available history · Aug 20, 2026 – Sep 01, 2026
Latest insider transactions
Form 4 filings from available history.| Company | Insider | Activity | Disclosed value | Filed (ET) |
|---|---|---|---|---|
CRNXCrinetics Pharmaceuticals, Inc. | Schilke TobinCF · IO | D · returnDerivative securitySEC filing ↗ | -$2.06MView disclosure → | |
CRNXCrinetics Pharmaceuticals, Inc. | Schilke TobinCF · IO | D · returnDerivative securitySEC filing ↗ | -$4.10MView disclosure → | |
CRNXCrinetics Pharmaceuticals, Inc. | Schilke TobinCF · IO | D · returnSEC filing ↗ | -$6.07MView disclosure → | |
CRNXCrinetics Pharmaceuticals, Inc. | Schilke TobinCF · IO | D · returnSEC filing ↗ | -$676kView disclosure → | |
CRNXCrinetics Pharmaceuticals, Inc. | Schilke TobinCF · IO | A · grantSEC filing ↗ | $0View disclosure → |
Latest Form 4 facts
Quick context from source filings
Latest open-market transaction
No latest transaction fact is available.
Latest buy
No open-market insider purchase is available.
Latest sale
No open-market insider sale is available.
Monthly open-market activity
Last 2 reported months · purchases and sales
No open-market purchases or sales in this history.
View exact monthly values
| Month | Purchases | Sales | Buy value | Sale value | Net value |
|---|---|---|---|---|---|
| Aug 2026 | 0 | 0 | $0.00 | $0.00 | $0.00 |
| Sep 2026 | 0 | 0 | $0.00 | $0.00 | $0.00 |
Net value is disclosed purchases minus sales, not profit. A dash means the value is unavailable.
Ownership and transaction size
Ownership and ticket size
Average P/S size—
Median P/S size—
Direct5
Indirect0
Sep 01, 2026return
Filing-only signals
Deterministic matches in this insider's history
Associated companies
Companies in the disclosed reporting history
Open-market buy performance
90-day forward return on this insider's open-market purchases
No open-market purchases in available history
A 90-day purchase return requires an open-market buy. No eligible purchases are recorded in this history.
Disclosed ownership
How reported shareholdings evolved
Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.
3 observations · Aug 20, 2026 – Sep 1, 2026. Window ends at the latest available report, not today.
Selected observation · Sep 1, 20260 shares reported
Inspect transaction View exact observations and source transactions
| Transaction date | Shares held after | Filed | Source |
|---|---|---|---|
| Aug 20, 2026 | 79,427 | Aug 24, 2026 | View transaction |
| Sep 1, 2026 | 71,471 | Sep 1, 2026 | View transaction |
| Sep 1, 2026 | 0 | Sep 1, 2026 | View transaction |
Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.
Schilke Tobin Insider Activity FAQ
SEC Form 4 context
Who is Schilke Tobin?
Schilke Tobin is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001678984.
Which companies has Schilke Tobin reported transactions for?
Crinetics Pharmaceuticals, Inc., Revance Therapeutics, Inc.
When was Schilke Tobin's latest insider buy?
No open-market insider purchase is available for this period.
When was Schilke Tobin's latest insider sale?
No open-market insider sale is available for this period.
Where can I see the original SEC filings?
Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.
Are performance metrics included?
The profile shows average and median 90-day stock returns after open-market purchases when price coverage is available. These are unadjusted stock returns, not realized trading gains. Win rates, benchmark-adjusted returns and conviction scores are not calculated.